[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568963":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":42,"collaborators":44,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":7,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Single Group Assignment","68Ga-DOTA\u002FNOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga\u002F18F-FAPI, and undergo PET\u002FCT imaging within the specificed time.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Haonan Yu, MD","CONTACT","+8613821000597","dreamadam@126.com",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Shaobo Yao, PhD","+8615122570279","yaoshaobo008@163.com",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":33,"coordinates":34},"Point",[35,36],117.17667,39.14222,{"lat":36,"lon":35},[39,40],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":20,"role":41,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":41,"investigatorFullName":20,"investigatorTitle":43,"investigatorAffiliation":25,"oldNameTitle":7,"oldOrganization":7},"Prof.",[45],{"name":25,"class":6},"100568963",false,"NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","80 Years",{"count":55,"type":56},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[61,62,63,64],"FAP-related Disease","Tumor","Positron Emission Tomography","Metastasis",[66,67,68],"PET\u002FCT","FAP","FAPI","2025-02-07",{"date":71,"type":72},"2025-02-11","ACTUAL",{"date":74,"type":72},"2022-03-01",{"date":76,"type":56},"2027-10-01",{"name":5,"class":6},1]